In the study published today in the journal Oncotarget, 10 men with metastatic prostate cancer resistant to androgen deprivation therapy and the androgen receptor antagonist enzalutamide were treated with pembrolizumab, a monoclonal antibody that binds to the PD-1 receptor.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
The research team led by Julie Graff, M.D.,says the data provide, for the first time, evidence for meaningful clinical activity for PD-1 blockade in men with metastatic prostate cancer that is resistant to androgen deprivation.
“It’s pretty remarkable, especially in light of the fact that many people doubted this approach could work at all,” said Graff, lead study author and an oncologist specializing in prostate cancer at the OHSU Knight Cancer Institute. “You don’t get responses like this with almost any other treatment.”
Men in the study had been treated with the androgen-receptor inhibitor enzalutamide, but their cancers showed signs of progression in spite of this therapy.
The three participants who responded to PD-1 blockade started with serum PSA levels of 46, 71 and 2,503 ng/ml. These PSA levels plummeted to less than 0.1 ng/ml after treatment, and these three patients remain free of progression at 30, 55 and 16 weeks of follow-up, respectively.
Important questions remain unanswered. It’s not yet known whether PD-1 blockade can improve survival in men with metastatic, castration-resistant prostate cancer, and it’s not possible to select which patients are likely to respond to the treatment.
Three of the 10 men in the study had stable disease at 30, 47 and 50 weeks, while the remaining four patients did not show evidence of clinical benefit. One of those four men died of prostate cancer.
In spite of the uncertainties, Graff and colleagues say the results in the men whose cancer responded to the treatment clearly stand out. Approved agents for metastatic, castration-resistant prostate cancer rarely produce PSA reduction to less than 0.2 ng/ml when enzalutamide has stopped working. Significant responses in liver metastases are also relatively uncommon with androgen receptor-targeting drugs or cytotoxic chemotherapies, they said.
The researchers had previously reported on two participants who were exceptional responders to immunotherapy and hypothesized that the immune-modifying actions of androgen receptor blockers such as enzalutamide might enhance immunotherapy. That prompted them to develop the phase II study to evaluate the efficacy of the PD-1 inhibitor pembrolizumab.
“There are considerable data showing that androgen-ablation may augment an anti-tumor immune response,” the researchers wrote in the paper describing early results. “Enzalutamide therapy represents a more potent form of androgen suppression and may therefore be associated with previously underappreciated immune modulatory effects.”
As these results report on the experience of the first 10 patients, they must be viewed as preliminary. The ongoing study, which is continuing to follow these men and has enrolled additional participants, will provide more robust answers about the potential benefits of PD-1 for men with metastatic prostate cancer, Graff says.
Future studies are in the planning stages.
Supported in part by a research grant from Investigator-Initiated Studies Program of Merck Sharp & Dohme Corp. Funds from the Bloomberg Kimmel Institute supported a portion of the laboratory work.
The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials.